{"prompt": "['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 6 of 81', 'Background treatment', 'Standard diuretic and comorbidity treatment', 'Indication', 'Treatment of chronic heart failure with preserved ejection fraction', 'Diagnosis and main criteria', 'Male and female patients aged 45 years or older, with chronic HF (NYHA', 'for inclusion /exclusion', 'class II or III), preserved left ventricular ejection fraction (LVEF 45%),', 'elevated natriuretic peptides, and previous HF decompensation will be', 'enrolled in this trial.', 'Main inclusion criteria:', 'Previous diagnosis of chronic HF', 'HF decompensation within 6 months prior to randomization, defined as', 'hospitalization for HF or intravenous (IV) diuretic treatment for HF', 'without hospitalization.', 'N-terminal pro brain natriuretic peptide (NT-proBNP) 300 or brain', 'natriuretic peptide (BNP) >100 pg/mL in sinus rhythm, or NT-proBNP', '>600 or BNP >200 pg/mL in atrial fibrillation within 30 days prior to', 'randomization', 'Diagnostic criteria of HFpEF by echocardiography assessed within', '12 months prior to randomization (most recent measurement must be', 'used to determine eligibility with no interim event signaling potential', 'deterioration in ejection fraction)', 'Left ventricular ejection fraction (LVEF) >45%', 'and', 'Structural changes indicated by at least one of the following', 'parameters:', 'Left ventricle (LV) hypertrophy (any of the following:', 'intraventricular septal or posterior wall thickness >1.1 cm, and/or', 'LV mass index >115 g/m\u00b2 in male and >95 g/m\u00b2 in female),', 'or', 'Left atrium (LA) enlargement (any of the following: left atrial', 'volume (LAV) index >29 ml/m\u00b2, or LAV >58 mL in male', 'and >52 mL in female patients, or LA area >20 cm\u00b2, or LA', 'diameter >40 mm in male and >38 mm in female patients)', 'NYHA class II or III at randomization', 'Main exclusion criteria:', 'Clinical instability at randomization, defined by', 'Any IV treatment within 24h prior to randomization, and/or', 'SBP >160 mmHg', 'SBP <110 mmHg and/or DBP <40 mmHg and/or symptomatic', 'hypotension', 'Resting heart rate (HR) <50 or >100 beats per minute (bpm)', 'Use of IV inotropes at any time between qualifying HF event and']['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 7 of 81', 'randomization', 'Previous diagnosis of reduced ejection fraction (EF) (EF <40%)', 'Hypertrophic obstructive cardiomyopathy, acute myocarditis,', 'amyloidosis, sarcoidosis, or pericardial disease', 'Primary valvular heart disease requiring surgery or intervention, or', 'within 3 months after valvular surgery or intervention, or active', 'endocarditis', 'Acute coronary syndrome, including unstable angina, Non ST-elevation', 'myocardial infarction or ST-elevation myocardial infarction, or Coronary', 'artery bypass grafting (CABG) within 60 days prior to randomization, or', 'indication for Percutaneous coronary intervention or CABG at the time of', 'randomization', 'Symptomatic carotid stenosis, or transient ischemic attack or stroke', 'within 60 days prior to randomization', 'Complex congenital heart disease', 'Non-cardiac comorbidity (any of the following)', 'Estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m2', 'calculated by Modification of Diet in Renal Disease formula', 'Hepatic insufficiency classified as Child-Pugh B or C', 'Morbid obesity with a body mass index >45 kg/m2', 'Malignancy or other non-cardiac condition limiting life expectancy', 'to <1 year, per physician judgment', 'Requires continuous home oxygen for severe pulmonary disease or', 'has interstitial lung disease', 'Patients with allergies, intolerance or hypersensitivity to', 'investigational drug or any of the excipients', 'Concurrent or anticipated use of nitrates or NO donors,', 'phosphodiesterase type V (PDE5) inhibitors, or a Soluble guanylate', 'cyclase (sGC) stimulator', 'Study design', 'Randomized parallel-group, placebo-controlled, double-blind, multi-center', 'trial', 'Methodology', 'Patients will be randomized 1:1:1 within 4 weeks after the Screening Visit to', 'either:', 'Placebo arm: placebo and sham up-titration at weeks 2, 4, and 6.', '10 mg arm: vericiguat, which will be started at 2.5 mg at randomization', 'and up-titrated to 5 mg at week 2 and to 10 mg at week 4, with sham', 'titration at week 6.', '15 mg arm: vericiguat, which will be started at 2.5 mg at randomization', 'and up-titrated to 5 mg at week 2, to 10 mg at week 4, and to 15 mg at', 'week 6.']\n\n###\n\n", "completion": "END"}